0001628280-21-017911.txt : 20210901 0001628280-21-017911.hdr.sgml : 20210901 20210831181843 ACCESSION NUMBER: 0001628280-21-017911 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210831 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210901 DATE AS OF CHANGE: 20210831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 211228135 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 ameh-20210831.htm 8-K ameh-20210831
0001083446false00010834462021-08-312021-08-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): September 1, 2021 (August 31, 2021)
 
APOLLO MEDICAL HOLDINGS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation)  File Number) Identification No.)
 
1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801
(Address of Principal Executive Offices) (Zip Code)
 
(626) 282-0288
Registrant’s Telephone Number, Including Area Code

 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockAMEHNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 8.01
Other Events
 
On August 31, 2021, Apollo Medical Holdings, Inc. ("ApolloMed") and CAIPA MSO, LLC ("CAIPA MSO"), a New York-based management services organization affiliated with Chinese American IPA d/b/a Coalition of Asian-American IPA ("CAIPA"), a leading independent practice association serving the greater New York City area, announced the closing of the strategic alliance and investment by ApolloMed in CAIPA MSO, effective August 27, 2021. ApolloMed purchased units of membership interest of CAIPA MSO, resulting in ApolloMed owning 30% of the post-closing total interests in CAIPA MSO on a fully diluted basis.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits

(d) Exhibits.
Exhibit No. Description
99.1 
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 APOLLO MEDICAL HOLDINGS, INC.
  
Date: September 1, 2021
By: /s/ Thomas S. Lam
 Name:
Title:
Thomas S. Lam, M.D., M.P.H.
Co-Chief Executive Officer and President


EX-99.1 2 exhibit991-pressreleaseacc.htm EX-99.1 Document

image_0.jpgimage_1.jpg
Apollo Medical Holdings, Inc. Announces Closing of CAIPA MSO Strategic Investment

ALHAMBRA, Calif., and NEW YORK, August 31, 2021 /PRNewswire/ -- Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, and CAIPA MSO, LLC (“CAIPA MSO”), a New York-based management services organization affiliated with Chinese American IPA d/b/a Coalition of Asian-American IPA (“CAIPA”), a leading independent practice association serving the greater New York City area, today announced the closing of the strategic alliance and investment by ApolloMed in CAIPA MSO, effective August 27, 2021.

With the closing of this transaction, which was previously announced in a press release on January 26, 2021, ApolloMed has completed the purchase of units of membership interest of CAIPA MSO resulting in ApolloMed owning 30% of the post-closing total interests in CAIPA MSO on a fully diluted basis. ApolloMed funded the transaction from cash on hand.

CAIPA MSO provides management, consulting, administrative, and other support services to professional healthcare service providers, including to CAIPA. With over 1,000 private practice providers covering over 70 specialties, CAIPA’s provider network provides medical services and care to approximately 500,000 patients. CAIPA is consistently one of the top performing provider networks in the region in quality and value-based financial performance, and its wholly owned subsidiary, CAIPA Care, LLC, is one of the only New York State Innovator Accountable Care Organizations, a value-based payment contracting designation by New York State that allows it to contract with payors at the most advanced payment levels to improve efficiencies and quality of care for patients.

Kenneth Sim, M.D., Executive Chairman and Co-Chief Executive Officer of ApolloMed, stated, “We are pleased to have consummated our strategic alliance with CAIPA MSO with the closing of this investment transaction, marking the beginning of what we anticipate will be a mutually productive and rewarding bi-coastal partnership that will benefit patients, physicians and the greater healthcare industry in the United States. This alliance marks ApolloMed’s entry into the New York market and is an important initial step forward in our expansion strategy. We are excited to be combining ApolloMed’s proprietary population health management and healthcare delivery platform, serving over 1.1 million patients, with CAIPA MSO’s extensive experience and member base of 500,000 in New York.”




George Liu, M.D., Chairman of CAIPA MSO, and President and Chief Executive Officer of CAIPA, stated, “CAIPA MSO is thrilled to be partnering with ApolloMed, an organization that is not only at the forefront of innovative technology but also has a proven track record of enabling providers to successfully participate in value-based care arrangements while building patient-centric local healthcare systems that deliver excellent patient outcomes and experiences. Leveraging CAIPA MSO’s experience in management and support services and CAIPA’s deep clinical expertise and best-in-class health professionals with ApolloMed’s core competencies will enable us to scale quickly and effectively in the greater New York area and beyond while demonstrating our ongoing commitment to empowering healthcare providers in the continuously evolving U.S. healthcare industry. We are excited to work with ApolloMed and look forward to driving continued improvement in our care delivery and patience experience.”

About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and a Next Generation Accountable Care Organization (NGACO). For more information, please visit www.apollomed.net.

About CAIPA MSO, LLC and Chinese American IPA, Inc. d/b/a Coalition of Asian-American IPA
Over the past 20 years, CAIPA continues to be a leading physician organization that delivers high-quality patient care in the most cost-effective manner in the greater New York City area. Headquartered in New York, New York, CAIPA’s subsidiaries include CAIPA MSO, a management services organization, and CAIPA Care, a New York State Innovator ACO. For more information, please visit www.caipa.com.





Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about ApolloMed's investment in CAIPA MSO, and ApolloMed's, CAIPA's, CAIPA MSO's, and CAIPA Care's growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, and strategic growth and expansion plans. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of ApolloMed's, CAIPA's, CAIPA MSO's, and CAIPA Care's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in ApolloMed's reports filed with the Securities and Exchange Commission, including, without limitation, the risk factors contained in ApolloMed’s Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Reports on Form 10-Q.


FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
investors@apollomed.net

Carolyne Sohn, The Equity Group
(415) 568-2255
csohn@equityny.com

CAIPA MSO
(212) 965-9888
info@caipa.com


EX-101.SCH 3 ameh-20210831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20210831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key EX-101.PRE 5 ameh-20210831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg GRAPHIC begin 644 image_0.jpg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image_1.jpg GRAPHIC begin 644 image_1.jpg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ameh-20210831_htm.xml IDEA: XBRL DOCUMENT 0001083446 2021-08-31 2021-08-31 0001083446 false 8-K 2021-08-31 APOLLO MEDICAL HOLDINGS, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock AMEH false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
    Document and Entity Information
    Aug. 31, 2021
    Cover [Abstract]  
    Document Type 8-K
    Document Period End Date Aug. 31, 2021
    Entity Registrant Name APOLLO MEDICAL HOLDINGS, INC.
    Entity Incorporation, State or Country Code DE
    Entity File Number 001-37392
    Entity Tax Identification Number 95-4472349
    Entity Address, Address Line One 1668 S. Garfield Avenue
    Entity Address, Address Line Two 2nd Floor
    Entity Address, City or Town Alhambra
    Entity Address, State or Province CA
    Entity Address, Postal Zip Code 91801
    City Area Code 626
    Local Phone Number 282-0288
    Written Communications false
    Soliciting Material false
    Pre-commencement Tender Offer false
    Pre-commencement Issuer Tender Offer false
    Title of 12(b) Security Common Stock
    Trading Symbol AMEH
    Entity Emerging Growth Company false
    Entity Central Index Key 0001083446
    Amendment Flag false
    EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.apollomed.net/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ameh-20210831.htm ameh-20210831.xsd ameh-20210831_lab.xml ameh-20210831_pre.xml exhibit991-pressreleaseacc.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ameh-20210831.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ameh-20210831.htm" ] }, "labelLink": { "local": [ "ameh-20210831_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20210831_pre.xml" ] }, "schema": { "local": [ "ameh-20210831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ameh", "nsuri": "http://www.apollomed.net/20210831", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ameh-20210831.htm", "contextRef": "ic0bb22e1da4645b9bfe3d638b1a5b7a2_D20210831-20210831", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.apollomed.net/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ameh-20210831.htm", "contextRef": "ic0bb22e1da4645b9bfe3d638b1a5b7a2_D20210831-20210831", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.apollomed.net/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001628280-21-017911-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-017911-xbrl.zip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